Murray S, Mendel C, Spigelman M
The Global Alliance for TB Drug Development (TB Alliance), New York, New York, USA.
Int J Tuberc Lung Dis. 2016 Dec 1;20(12):38-41. doi: 10.5588/ijtld.16.0069.
The recent approval of new tuberculosis (TB) drugs raises hope for new and more effective anti-tuberculosis treatment regimens. The Global Alliance for TB Drug Development (TB Alliance) is committed to ensuring that new anti-tuberculosis drugs fulfill the needs of patients, their families and the local health services that serve the communities. Here we present highlights of the TB Alliance's pipeline of regimen development, with novel regimens for patients with drug-susceptible, multidrug-resistant and extensively drug-resistant TB. The ongoing clinical trials (STAND, NC-005, Nix-TB and LIN-CL001) are outlined and their rationale and goals presented.
近期新型结核病药物获批，为全新且更有效的抗结核治疗方案带来了希望。全球结核病药物研发联盟（结核病联盟）致力于确保新型抗结核药物能够满足患者、其家庭以及服务社区的当地医疗卫生服务机构的需求。在此，我们介绍结核病联盟治疗方案研发进程中的亮点，包括针对药物敏感型、耐多药型及广泛耐药型结核病患者的新型治疗方案。文中概述了正在进行的临床试验（STAND、NC - 005、Nix - TB和LIN - CL001），并阐述了其原理及目标。
